“Online survey of COVID-19 immunization and infection in patients with systemic juvenile idiopathic arthritis and adult-onset still’s disease.”
| dc.contributor.author | Marques, Mariana C. | |
| dc.contributor.author | Paul, Subrata | |
| dc.contributor.author | Lake, Carol | |
| dc.contributor.author | Bergeron, Ly-Lan | |
| dc.contributor.author | Sinha, Rashmi | |
| dc.contributor.author | Peixoto, Luciana | |
| dc.contributor.author | Twilt, Marinka | |
| dc.contributor.author | Ombrello, Michael J. | |
| dc.date.accessioned | 2023-11-26T01:02:40Z | |
| dc.date.available | 2023-11-26T01:02:40Z | |
| dc.date.issued | 2023-11-21 | |
| dc.date.updated | 2023-11-26T01:02:40Z | |
| dc.description.abstract | Abstract Background Patients with systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD) have been under-represented in studies about safety of the COVID-19 immunization. We aimed to inquire about the safety and tolerability of COVID-19 immunization in this population. Methods An anonymous online survey on closed Facebook groups for patients and parents with self-reported sJIA/AOSD was posted from June 27th until August 30th, 2022. Continuous variables were analyzed using t-tests or the Mann-Whitney U test if non-normally distributed. Fisher`s tests were used for categorical variables. Results Of a total of 167 responses, 17 were excluded. Ninety-nine patients received the COVID-19 immunization, and 51 patients did not. Patients in both immunized and unimmunized groups had a similar history of disease complications such as macrophage activation syndrome (50% vs. 49%), lung disease (17% vs. 29%), arthritis (51% vs. 50%), and pericarditis/myocarditis (10% vs. 8%). Unimmunized patients were younger (median age 8 yo vs. 12 yo, p < 0.001) and had a higher incidence of a history of disease flare or severe side effects with other immunizations (24% vs. 4%, p < 0.001). Thirty-nine patients reported mostly mild immunization side effects. Severe side effects included 6 reports of disease flare and 2 reports of cardiac side effects (pericarditis and atrial fibrillation). Seven patients reported side effects lasting ≥ 8 days. Three patients developed AOSD following COVID-19 immunization, and 2 of them had the only hospital admissions for immunization side effects. Regarding COVID-19 infection, 46 patients were infected without full immunization, and 33 were infected after 2 doses of immunization. There was one hospitalization in the immunized group, compared to one ICU admission leading to death in the non-immunized group. There was a trend (p > 0.05) toward a higher risk of disease flare after COVID-19 infection among non-immunized patients (43%), compared to immunized patients (24%). Conclusions The COVID-19 immunization was well tolerated by sJIA/AOSD patients even in this group of patients with severe disease. There was a low incidence of disease flare with immunization. Most immunization side effects were mild and lasted < 7 days. The only ICU admission and death from COVID-19 infection occurred in unimmunized subjects. | |
| dc.identifier.citation | Pediatric Rheumatology. 2023 Nov 21;21(1):139 | |
| dc.identifier.uri | https://doi.org/10.1186/s12969-023-00911-x | |
| dc.identifier.uri | https://hdl.handle.net/1880/117590 | |
| dc.identifier.uri | https://doi.org/10.11575/PRISM/42433 | |
| dc.language.rfc3066 | en | |
| dc.rights.holder | This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply | |
| dc.title | “Online survey of COVID-19 immunization and infection in patients with systemic juvenile idiopathic arthritis and adult-onset still’s disease.” | |
| dc.type | Journal Article |